Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zeo ScientifiXZEOX 45 3-Year EBITDA Growth Rate is 16.50% as of Apr. 2026. GuruFocus rates ZEOX with a GF Score™ of 45/100 and a GF Value™ of $2.62 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,127 Biotechnology companies, Zeo ScientifiX ranks better than 51.91% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 16.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 28.10% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 12.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Zeo ScientifiX was 38.40% per year. The lowest was -399.30% per year. And the median was -7.30% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Zeo ScientifiX 3-Year EBITDA Growth Rate Related Terms
ZEOX vs FBLG, INAB, XBIO: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Zeo ScientifiX's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zeo ScientifiX 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Zeo ScientifiX's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 16.50% mean?
Zeo ScientifiX (ZEOX) has a 3-Year EBITDA Growth Rate of 16.50% as of Apr. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Zeo ScientifiX and its competitors. According to the industry distribution chart, Zeo ScientifiX ranks #542 out of 1127 companies in the Biotechnology industry, placing it in the top 48.1%.
Is Zeo ScientifiX's 3-Year EBITDA Growth Rate too high?
Zeo ScientifiX's current 3-Year EBITDA Growth Rate is 16.50%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.70. Zeo ScientifiX's value of 16.50% is 12.2% above this industry median. Based on the distribution chart, Zeo ScientifiX ranks #542 out of 1127 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zeo ScientifiX has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zeo ScientifiX's 3-Year EBITDA Growth Rate compare to FBLG and INAB?
According to the Biotechnology industry distribution chart, Zeo ScientifiX ranks #542 out of 1127 companies for 3-Year EBITDA Growth Rate. This puts Zeo ScientifiX in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.70. Zeo ScientifiX's value of 16.50% is 12.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.70, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zeo ScientifiX's current 3-Year EBITDA Growth Rate of 16.50% is 12.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Zeo ScientifiX and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zeo ScientifiX's current 3-Year EBITDA Growth Rate is 16.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zeo ScientifiX stock overvalued right now?
Based on GuruFocus' analysis, Zeo ScientifiX (ZEOX) is currently considered Possible Value Trap. The stock's GF Value™ is $2.62, compared to a current price of $1.20 — trading 54.2% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 16.50% and 12.2% above the Biotechnology industry median of 14.70. Zeo ScientifiX's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Zeo ScientifiX (ZEOX), the current 3-Year EBITDA Growth Rate is 16.50% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zeo ScientifiX (ZEOX) Overvalued in 2026?
Based on GuruFocus' analysis, Zeo ScientifiX stock appears to be undervalued.
The current stock price of $1.20 is trading 54.2% below its estimated GF Value™ of $2.62.
GuruFocus considers Zeo ScientifiX to be Possible Value Trap.
Key valuation signals for ZEOX:
3-Year EBITDA Growth Rate: 16.50%
GF Value™: $2.62 vs. price of $1.20 (54.2% below fair value)
Industry Position: 12.2% above the Biotechnology median (#542 of 1127)
No single metric tells the full story. See the ZEOX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zeo ScientifiX Inc is a clinical-stage biopharmaceutical company located inside Nova Southeastern University's Collaborative Center for Research in Davie, Florida. The Company is a clinical-stage biopharmaceutical company principally focusing on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company's proprietary products, including Zofin, are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and Patient Pure X (PPX ), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood (RAAM Products).
45GF Score
Get the complete analysis for ZEOX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZEOX has been successfully added to your 
